Citadel Advisors
FDMT icon

Citadel Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Citadel Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.46M Buy
264,096
+244,207
+1,228% +$2.13M ﹤0.01% 5660
2025
Q4 		$149K Buy
+19,889
New +$202K ﹤0.01% 11329
2025
Q3 		– Sell
-192,239
Closed -$1.15M – 13143
2025
Q2 		$713K Sell
192,239
-138,972
-42% -$489K ﹤0.01% 7798
2025
Q1 		$1.07M Sell
331,211
-273,881
-45% -$1.29M ﹤0.01% 6813
2024
Q4 		$3.37M Buy
605,092
+477,444
+374% +$3.75M ﹤0.01% 4637
2024
Q3 		$1.38M Buy
127,648
+54,450
+74% +$904K ﹤0.01% 6221
2024
Q2 		$1.54M Sell
73,198
-15,031
-17% -$377K ﹤0.01% 5806
2024
Q1 		$2.81M Buy
88,229
+69,671
+375% +$1.78M ﹤0.01% 4893
2023
Q4 		$376K Sell
18,558
-124,662
-87% -$1.64M ﹤0.01% 8694
2023
Q3 		$1.82M Buy
143,220
+124,335
+658% +$2.08M ﹤0.01% 5388
2023
Q2 		$341K Buy
18,885
+14,013
+288% +$258K ﹤0.01% 8758
2023
Q1 		$83.8K Buy
+4,872
New +$94.7K ﹤0.01% 11502
2022
Q4 		– Sell
-122,459
Closed -$1.89M – 15011
2022
Q3 		$984K Sell
122,459
-102,483
-46% -$928K ﹤0.01% 7029
2022
Q2 		$1.57M Buy
224,942
+176,409
+363% +$1.72M ﹤0.01% 6046
2022
Q1 		$733K Buy
48,533
+16,656
+52% +$262K ﹤0.01% 8451
2021
Q4 		$700K Buy
31,877
+18,041
+130% +$442K ﹤0.01% 8842
2021
Q3 		$373K Sell
13,836
-13,476
-49% -$384K ﹤0.01% 10569
2021
Q2 		$658K Buy
27,312
+7,696
+39% +$236K ﹤0.01% 9391
2021
Q1 		$851K Sell
19,616
-32,847
-63% -$1.45M ﹤0.01% 8504
2020
Q4 		$2.17M Buy
+52,463
New +$2.17M ﹤0.01% 5184

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's FDMT Position: Q1 2026 in Review

Citadel Advisors increased its 4D Molecular Therapeutics (FDMT) stake by 1,228% in Q1 2026, buying an estimated $2.13M and bringing the position to 264,096 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5660.

Citadel Advisors first reported a position in FDMT in Q4 2020 and has held it in 20 quarters since. The position peaked at $3.37M in Q4 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Citadel Advisors held 264,096 shares of 4D Molecular Therapeutics worth $2.46M as of Q1 2026.
  • Citadel Advisors bought 244,207 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.13M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5660 holding.
  • Citadel Advisors first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Citadel Advisors's 4D Molecular Therapeutics position peaked at $3.37M in Q4 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.